FOLH1 and prostate cancer: We excluded 1782 patients with PSMA PET/CT confirmed intermediate-risk localized disease (n = 74), high-risk localized disease (n = 641), castrate-resistant disease (n = 144), recurrent disease (n = 919), and subsequent non-prostate cancer diagnosis (n = 4).